Chemistry:Opigolix

From HandWiki
Short description: Chemical compound
Opigolix
Opigolix.svg
Clinical data
Other namesASP-1707
Routes of
administration
By mouth
Drug classGnRH modulator; GnRH antagonist; Antigonadotropin
Identifiers
CAS Number
PubChem CID
UNII
KEGG
Chemical and physical data
FormulaC25H19F3N4O5S
Molar mass544.51 g·mol−1
3D model (JSmol)

Opigolix (INN, USAN; developmental code name ASP-1707) is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which was under development by Astellas Pharma for the treatment of endometriosis and rheumatoid arthritis.[1][2] It was also under investigation for the treatment of prostate cancer.[1] It reached phase II clinical trials for both endometriosis and rheumatoid arthritis prior to the discontinuation of its development in April 2018.[1]

See also

References

  1. 1.0 1.1 1.2 "Opigolix - Astellas Pharma - AdisInsight". http://adisinsight.springer.com/drugs/800032657. 
  2. "Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain". Women's Health 11 (1): 19–28. 2015. doi:10.2217/whe.14.68. PMID 25581052. 

External links